Exome sequencing reveals a novel Moroccan founder mutation inSLC19A3as a new cause of early-childhood fatal Leigh syndrome
Open Access
- 18 February 2013
- journal article
- case report
- Published by Oxford University Press (OUP) in Brain
- Vol. 136 (3), 882-890
- https://doi.org/10.1093/brain/awt013
Abstract
Leigh syndrome is an early onset, often fatal progressive neurodegenerative disorder caused by mutations in the mitochondrial or nuclear DNA. Until now, mutations in more than 35 genes have been reported to cause Leigh syndrome, indicating an extreme genetic heterogeneity for this disorder, but still only explaining part of the cases. The possibility of whole exome sequencing enables not only mutation detection in known candidate genes, but also the identification of new genes associated with Leigh syndrome in small families and isolated cases. Exome sequencing was combined with homozygosity mapping to identify the genetic defect in a Moroccan family with fatal Leigh syndrome in early childhood and specific magnetic resonance imaging abnormalities in the brain. We detected a homozygous nonsense mutation (c.20C>A; p.Ser7Ter) in the thiamine transporter SLC19A3. In vivo overexpression of wild-type SLC19A3 showed an increased thiamine uptake, whereas overexpression of mutant SLC19A3 did not, confirming that the mutation results in an absent or non-functional protein. Seventeen additional patients with Leigh syndrome were screened for mutations in SLC19A3 using conventional Sanger sequencing. Two unrelated patients, both from Moroccan origin and one from consanguineous parents, were homozygous for the same p.Ser7Ter mutation. One of these patients showed the same MRI abnormalities as the patients from the first family. Strikingly, patients receiving thiamine had an improved life-expectancy. One patient in the third family deteriorated upon interruption of the thiamine treatment and recovered after reinitiating. Although unrelated, all patients came from the province Al Hoceima in Northern Morocco. Based on the recombination events the mutation was estimated to have occurred 1250–1750 years ago. Our data shows that SLC19A3 is a new candidate for mutation screening in patients with Leigh syndrome, who might benefit from high doses of thiamine and/or biotin. Especially, Moroccan patients with Leigh syndrome should be tested for the c.20C>A founder mutation in SLC19A3.Keywords
This publication has 23 references indexed in Scilit:
- Thiamine Pyrophosphokinase Deficiency in Encephalopathic Children with Defects in the Pyruvate Oxidation PathwayAmerican Journal of Human Genetics, 2011
- Revisiting Mendelian disorders through exome sequencingHuman Genetics, 2011
- A map of human genome variation from population-scale sequencingNature, 2010
- Biotin-Responsive Basal Ganglia Disease in Ethnic Europeans With Novel SLC19A3 MutationsArchives of Neurology, 2010
- Sequencing technologies — the next generationNature Reviews Genetics, 2009
- Mutations in a Thiamine-Transporter Gene and Wernicke's-like EncephalopathyThe New England Journal of Medicine, 2009
- Leigh syndrome due to compound heterozygosity of dihydrolipoamide dehydrogenase gene mutations. Description of the first E3 splice site mutationEuropean Journal of Pediatrics, 2003
- Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomicsProceedings of the National Academy of Sciences of the United States of America, 2003
- Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafnessNature Genetics, 1999
- Molecular genetic characterization of an X‐linked form of Leigh's syndromeAnnals of Neurology, 1993